{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T08:06:26Z","timestamp":1769328386570,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.bpg.2009.11.001","type":"journal-article","created":{"date-parts":[[2010,3,5]],"date-time":"2010-03-05T09:41:57Z","timestamp":1267782117000},"page":"19-26","source":"Crossref","is-referenced-by-count":15,"title":["Role of chemotherapy in gastric MALT lymphoma, diffuse large B-cell lymphoma and other lymphomas"],"prefix":"10.1016","volume":"24","author":[{"given":"Markus","family":"Raderer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Paul de Boer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bpg.2009.11.001_bib1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3324\/haematol.11835","article-title":"Dissemination patterns in non-gastric MALT lymphoma","volume":"93","author":"de Boer","year":"2008","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.bpg.2009.11.001_bib2","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1158\/1078-0432.CCR-04-2282","article-title":"High relapse rate in patients with MALT lymphoma warrants lifelong follow-up","volume":"11","author":"Raderer","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.bpg.2009.11.001_bib3","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1200\/JCO.1995.13.10.2524","article-title":"Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression","volume":"13","author":"Hammel","year":"1995","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.bpg.2009.11.001_bib4","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1200\/JCO.2005.05.660","article-title":"Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy","volume":"23","author":"Levy","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bpg.2009.11.001_bib5","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2141.2008.07486.x","article-title":"Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial","volume":"144","author":"Hancock","year":"2009","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.bpg.2009.11.001_bib6","first-page":"1583","article-title":"Low-grade B cell lymphomas of mucosa-associated lymphoid tissue (MALT-type) require CD40-mediated signaling and Th2-type cytokines for in vitro growth and differentiation","volume":"150","author":"Greiner","year":"1997","journal-title":"Am J Pathol"},{"issue":"8871","key":"10.1016\/j.bpg.2009.11.001_bib7","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/0140-6736(93)91408-E","article-title":"The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori","volume":"342","author":"Hussell","year":"1993","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bpg.2009.11.001_bib8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/(SICI)1096-9896(199602)178:2<122::AID-PATH486>3.0.CO;2-D","article-title":"Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue","volume":"178","author":"Hussell","year":"1996","journal-title":"J Pathol"},{"issue":"2","key":"10.1016\/j.bpg.2009.11.001_bib9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/path.1711690208","article-title":"Proliferation and differentiation of tumour cells from B-cell lymphoma of mucosa-associated lymphoid tissue in vitro","volume":"169","author":"Hussell","year":"1993","journal-title":"J Pathol"},{"issue":"6","key":"10.1016\/j.bpg.2009.11.001_bib10","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1023\/A:1008396618983","article-title":"Gastric MALT lymphoma: from concept to cure","volume":"10","author":"Isaacson","year":"1999","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.bpg.2009.11.001_bib11","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1200\/JCO.2002.05.117","article-title":"Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study","volume":"20","author":"Jager","year":"2002","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bpg.2009.11.001_bib12","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/annonc\/mdl126","article-title":"Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial","volume":"17","author":"Jager","year":"2006","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.bpg.2009.11.001_bib13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1023\/A:1008310708853","article-title":"Preliminary results on the activity of oxaliplatin (L-OHP) in refractory\/recurrent non-Hodgkin's lymphoma patients","volume":"10","author":"Germann","year":"1999","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.bpg.2009.11.001_bib14","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/cncr.21219","article-title":"Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma","volume":"104","author":"Oki","year":"2005","journal-title":"Cancer"},{"issue":"33","key":"10.1016\/j.bpg.2009.11.001_bib15","doi-asserted-by":"crossref","first-page":"8442","DOI":"10.1200\/JCO.2004.00.8532","article-title":"Phase II Study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma","volume":"23","author":"Raderer","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bpg.2009.11.001_bib16","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1054\/bjoc.2001.2036","article-title":"Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer","volume":"85","author":"Chau","year":"2001","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.bpg.2009.11.001_bib17","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1023\/A:1012501305214","article-title":"Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma","volume":"12","author":"Machover","year":"2001","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.bpg.2009.11.001_bib18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1385\/MO:22:1:057","article-title":"Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial","volume":"22","author":"Aviles","year":"2005","journal-title":"Med Oncol"},{"issue":"5","key":"10.1016\/j.bpg.2009.11.001_bib19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/gut.2005.083022","article-title":"Successful antibiotic treatment of helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas","volume":"55","author":"Raderer","year":"2006","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.bpg.2009.11.001_bib20","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/annonc\/mdg492","article-title":"Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP)","volume":"14","author":"Wohrer","year":"2003","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.bpg.2009.11.001_bib21","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000074641","article-title":"Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma","volume":"65","author":"Raderer","year":"2003","journal-title":"Oncology"},{"issue":"8","key":"10.1016\/j.bpg.2009.11.001_bib22","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bpg.2009.11.001_bib23","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1200\/JCO.2005.08.128","article-title":"Clinical activity of rituximab in gastric marginal zone non-hodgkin's lymphoma resistant to or not eligible for anti-helicobacter pylori therapy","volume":"23","author":"Martinelli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bpg.2009.11.001_bib24","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/annonc\/mdh261","article-title":"Rituximab, cyclophosphamide, doxorubicin, vincristine and\u00a0prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma","volume":"15","author":"Wohrer","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bpg.2009.11.001_bib25","author":"Troch","year":"2009","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.bpg.2009.11.001_bib26","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"26","key":"10.1016\/j.bpg.2009.11.001_bib27","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1200\/JCO.2005.55.017","article-title":"Current treatment approaches for mantle-cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bpg.2009.11.001_bib28","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1023\/A:1008278605751","article-title":"Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma","volume":"8","author":"Ketterer","year":"1997","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.bpg.2009.11.001_bib29","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bpg.2009.11.001_bib30","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/MCG.0b013e3180f62b12","article-title":"Primary gastrointestinal follicular lymphoma: a clinicopathologic study of 13\u00a0cases from Taiwan","volume":"42","author":"Huang","year":"2008","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"10.1016\/j.bpg.2009.11.001_bib31","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/annonc\/mdg168","article-title":"Primary follicular lymphoma of the gastrointestinal tract: a study of 25 cases and a literature review","volume":"14","author":"Damaj","year":"2003","journal-title":"Ann Oncol"},{"issue":"28","key":"10.1016\/j.bpg.2009.11.001_bib32","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bpg.2009.11.001_bib33","first-page":"521","article-title":"Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years?","volume":"136","author":"Ferrucci","year":"2007","journal-title":"Br\u00a0J\u00a0Haematol"},{"issue":"28","key":"10.1016\/j.bpg.2009.11.001_bib34","doi-asserted-by":"crossref","first-page":"7050","DOI":"10.1200\/JCO.2005.04.031","article-title":"Treatment results in localised primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02\/96)","volume":"23","author":"Koch","year":"2005","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.bpg.2009.11.001_bib35","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1200\/JCO.2007.13.6929","article-title":"Phase II Study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-Cell lymphoma: southwest oncology group study 0014","volume":"26","author":"Persky","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bpg.2009.11.001_bib36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.bpg.2009.11.001_bib37","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1093\/annonc\/mdf178","article-title":"Chemotherapy for management of localised high-grade gastric B-cell lymphoma: how much is necessary?","volume":"13","author":"Raderer","year":"2002","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.bpg.2009.11.001_bib38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1089\/cbr.2008.0507","article-title":"Rituximab and chemotherapy in primary gastric lymphoma","volume":"24","author":"Aviles","year":"2009","journal-title":"Cancer Biother Radiopharm"},{"issue":"1","key":"10.1016\/j.bpg.2009.11.001_bib39","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/01.sla.0000129354.31318.f1","article-title":"The role of surgery in primary gastric lymphoma: results of a controlled clinical trial","volume":"240","author":"Aviles","year":"2004","journal-title":"Ann Surg"},{"issue":"7","key":"10.1016\/j.bpg.2009.11.001_bib40","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.2006.07.0722","article-title":"CHOP alone compared with CHOP plus radiotherapy for localised aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adult","volume":"25","author":"Bonnet","year":"2007","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Best Practice &amp; Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691809001516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691809001516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,26]],"date-time":"2019-05-26T17:09:22Z","timestamp":1558890562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691809001516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S1521691809001516"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2009.11.001","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}